The Deep Non-Thinker

​
April 27, 2023

Lock up your authors! ChatGPT is here! And it's coming for your IP!

The internet is awash with content written about, or written by, the new chat-bot in town, ChatGPT. But what is ChatGPT? And what does it mean for the IP world?

ChatGPT, along with its geeky sibling Codex, artistic cousins Midjourney and Stable Diffusion, and a host of others already or soon to be released, are examples of "generative AI", whose emergence has the potential to fundamentally change the way we interact with technology. Software companies, desperate to cash in on the promise of increased productivity and newly terrified of becoming obsolete, are racing to integrate these new tools into their products. Others warn that the sudden and widespread deployment of generative AI could lead to an onslaught of dangerous consequences, including propagation of misinformation and fraud. Many are worried about the potential of generative AI to dilute and devalue human work, and to replace human jobs completely.

In this first of a series of three articles, I will explain what generative AI is and set out the strengths and limitations of the technology. In subsequent articles, I will discuss how generative AI may impact those creating and protecting IP.

What is generative AI?

Artificial intelligence (AI) refers to computer software that learns how to perform tasks by finding patterns in data, rather than being programmed by humans. Generative AI is a particular flavour of AI in which the computer generates new data that resembles data from which it has learned, such as text, audio, video or images.

In recent years, a few landmark innovations, along with increasing availability of data and sufficiently powerful computers, have provided the necessary conditions for generative AI to flourish into the headline-grabbing behemoth it is today, with ChatGPT placing the technology firmly in the public eye. By now, most of us have had a chance to marvel at the amazing feats of generative AI, whether it is conjuring up a life-like image of an astronaut riding a horse, or explaining a mathematical algorithm in the style of a New York mobster.

How does it do that?

AI uses mathematical models to represent patterns in data. The model of choice for most AI applications is the (artificial) neural network, which specifies a sequence of mathematical operations that can be visualised as layers of artificial neurons and connections, loosely analogous to the physical components of a real brain.

As with a real brain, a neural network's ability to perform a task depends on the configuration of neurons and connections in the network, the quality and volume of data to which it has been exposed, and the way in which it has been taught. Generally speaking, the bigger (more neurons) and deeper (more layers) the network, the greater its capacity to learn – in theory, a big enough neural network can learn to represent any relationship that may be present in a set of data. But size comes at a cost: the bigger the network, the greater its appetite for data. And neural networks for generative AI can be ravenous indeed. The GPT-4 network behind the latest version of ChatGPT, for example, has of the order of a trillion neurons, and the cost of resources needed for its training likely ran into tens of millions of dollars as it was fed terabytes of text data scraped from the internet.

Size is not everything. The skill of an AI researcher lies in designing the configuration (architecture) of a network's neurons and connections to encourage it to find patterns in data, whilst keeping its hunger levels in check. Architectures are incrementally tweaked and improved all the time, but every so often there is a landmark innovation which results in a technological step change. For language-generating models (aka large language models, LLMs), this step change came from the invention of the "transformer" (the "T" in GPT), which is a neural network that uses "attention layers" to identify context-specific relationships between words (tokens) and their positions in passages of text (sequences). Things like New York's organised criminals frequently ending statements with a question, see? Attention layers provide the model with awareness of grammatical and semantic structures, and this is part of the magic that enables ChatGPT's musings to be consistently coherent and plausible. A much older, but analogous, invention is the convolutional neural network, which uses convolutional layers to identify spatial relationships between features in images, such as noticing that a person riding a horse always sits on the horse's back, rather than hovering above its head.

But these innovations alone don't explain the uncanny and sometimes eerily human-like outputs of ChatGPT. For that, an additional helping of secret sauce is needed, and that is the injection of randomness. Most generative AI models are not deterministic, and their outputs vary randomly for a given input. By adding randomness during training, the model learns to handle unexpected variations, and accordingly to generalise more effectively to situations it has not seen before. As a concrete example, ChatGPT predicts a most likely next word in dependence on its prompt and all of the words it has already typed, but with a small built-in probability of predicting a less likely word. This unpredictability is key to the model's training, with the bonus effect of making ChatGPT behave more like a human and less like a robot.

What's the catch?

A plausible output is not necessarily a good output. Generative AI sees only in patterns, and lacks any deeper understanding of its inputs or outputs. Although the reasoning ability of generative AI language models is continually improving, for now they still fail at relatively simple logic puzzles. An illuminating example is ChatGPT insisting that two kilograms of bricks weighs the same as one kilogram of feathers: the model has recognised the set-up of a common trick question, but erroneously generalised its clever-clogs answer to a different set of facts. AI practitioners would classify such behaviour as over-fitting. For similar reasons, a generative AI model for writing computer code is not guaranteed to produce the most logical coding solutions, only those similar to what it has seen in its training data. Generative AI is ultimately a parrot, not a deep thinker.

Another problem is that a generative AI model's memory of its training data is stored implicitly via the connections between its neurons, and as any forgetful human can tell you, this is not a reliable way of accurately storing information. Accordingly, the AI's internal representation of the training data is somewhat fuzzy – a blurry snapshot of the internet from when the model was trained. Any content created by such a model is dependent on this internal representation, as well as any data fed into it at execution time (e.g. a prompt/document to be summarised/image to be modified/random noise). The extent to which the model has inserted its own knowledge is not always evident, and this imports an inherent lack of reliability into any content it creates. In view of these consideration, perhaps the greatest peril of the current crop of generative AI models is that despite their shortcomings, they often present their answers with unflappable confidence.

The final consideration is the way in which generative AI models are trained, and who is the teacher. AI models are trained to maximise some sort of score or objective. This may be uncontroversial if the objective simply measures how faithfully the model reproduces patterns in data. However, to get ChatGPT to answer questions in a manner that is appealing to humans, a more complex objective, relying on human feedback, is needed. The humans designing the objective and providing the feedback wield great power over the eventual outputs of the model. And these humans ultimately serve the interests of the commercial entity funding the process. ChatGPT's creator, OpenAI, is the first to admit this, but the potential centralisation of power to Big Tech's biggest guns has alarm bells ringing. On the other hand, a flurry of research activity in the open source software community has already succeeded in replicating and scaling down much of the functionality of generative AI models to the extent that they can be trained and run on a laptop, which may go some way to democratising access to the technology. Irrespective of who wins the race for generative AI supremacy, regulation will play an important role in keeping the balance of power and responsibility in check.

Conclusion

Generative AI is a powerful technology that is already transforming the way humans work and live. It is an illogical but persuasive beast, and its safe use demands a great deal of critical thinking, coupled with an awareness of its limitations and biases. The current generation of generative AI tools have a dangerous tendency to confidently deliver fabrications as truth – surely their most human-like quality of all.

In the next article in this series, I will look at the first touchpoint between generative AI and IP, which is: do generative AI models copy the content on which they are trained? Are the content authors' IP rights infringed in this process, and how should the law deal with this?

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​